MIP-1 (CCL3) is a Downstream Target of FGFR3 and RAS/MAPK Signaling in Multiple Myeloma

Authors:
Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V, Wei E, Roodman D, Claudio J, Bergsagel L, Stewart AK
In:
Source: Blood
Publication Date: (2006)
Issue: 108(10): 3465-71
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cells used in publication:
NCI-H929 [H929]
Species: human
Tissue Origin: blood
NCTC clone 929
Species: mouse
Tissue Origin: Connective tissue proper
Platform:
Nucleofectorâ„¢ I/II/2b
Abstract
To dissect the mechanism of FGFR3 oncogenesis in MM, we used 3 FGFR selective kinase inhibitors-CHIR258, PD173074, and SU5402-and FGFR3-specific siRNA to modulate FGFR3 activity. Conversely, the ligand FGF was used to stimulate FGFR3 function in human MM cells. The transcriptional response to FGFR3 modification was recorded, and gene expression changes common to all 5 modifiers were documented. Ten genes were commonly regulated. Macrophage inflammatory protein-1 alpha (MIP-1alpha) was the single most differentially altered gene. MIP-1 alpha promoter function, gene expression, and protein secretion were each down-regulated following inhibition of FGFR3 signaling. Down-regulation of MIP-1 alpha was not, however, observed following FGFR3 inhibition in MM cells with RAS mutations implicating RAS-MAPK in MIP-1 alpha regulation. As confirmation, inhibition of ERK1 also down-regulated MIP-1 alpha in FGFR3 inhibitor-resistant cells harboring RAS mutations. MIP-1 alpha is implicated in the survival and proliferation of MM cells and the pathogenesis of MM bone disease. Our observation is the first to directly link an initiating IgH translocation not only to MM-cell growth and survival but also to the disease-associated bone disease.